VERA logo

VERA THERAPEUTICS INC

VERANASDAQ
πŸ† #1882 by market capEarnings Feb 24 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track VERA
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.84B
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
67.9%
High
πŸ’΅FCF Margin
-3659.1%
Thin
βš–οΈP/S Ratio
179.0x
Expensive
Otter Score
44
Weak
No chart data available for VERA.

Trading Snapshot

Day Range
β€”
52-Week Range
$25.08 – $56.05
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
72.3M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$10M
P/E Ratio
-4.3
P/S Ratio
179.0x
EPS (TTM)
$-5.76
Dividend Yield
0.00%
Dilution (1yr)
+17.0%
VERA logo

VERA THERAPEUTICS INC

VERA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$315Mβ–² +88.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$242Mβ–² +78.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.2Mβ–² +17.0% YoY
StockOtter Β· stockotter.space

About VERA THERAPEUTICS INC

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
44/100
Analyst data unavailable.

Latest News & Updates

News unavailable.